Actions
>>/45462/ Dividend of biowarfare research The product first described yesterday by CNN is the result of a convoluted convergence of U.S. and Canadian federal agencies and industrial partners that's typical for treatments of potential value against biowarfare and bioterrorism. https://www.forbes.com/sites/davidkroll/2014/08/05/ebola-secret-serum-small-biopharma-the-army-and-big-tobacco/#245e7cdc358e